Casdin Capital 13F holdings, Q1 2023
Holdings as of March 31, 2023 · filings on SEC EDGAR · latest filing →
Casdin Capital disclosed 40 US equity positions worth $1.2bn in its Q1 2023 13F filing. The largest position was BLFS at 13.6% of the reported book, followed by SRPT and RLAY. Against the Q4 2022 filing, it opened 2 new positions, added to 10 and reduced 10 among the top 40 holdings.
What did Casdin Capital own in Q1 2023? Top 40 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q4 2022 |
|---|---|---|---|---|---|---|---|
| 1 | BLFS BIOLIFE SOLUTIONS INC | Healthcare | 13.6% | $164.7m | 7,571,535 | 0% | held |
| 2 | SRPT SAREPTA THERAPEUTICS INC | Healthcare | 13.2% | $159.9m | 1,160,000 | -12% | reduced |
| 3 | RLAY RELAY THERAPEUTICS INC | Healthcare | 7.8% | $93.9m | 5,698,574 | 88% | added |
| 4 | EQRX INC | 6.3% | $76.7m | 39,527,669 | 0% | held | |
| 5 | ILMN ILLUMINA INC | Healthcare | 5.3% | $64.0m | 275,000 | -29% | reduced |
| 6 | ALNY ALNYLAM PHARMACEUTICALS INC | Healthcare | 4.5% | $54.1m | 270,000 | -26% | reduced |
| 7 | NTLA INTELLIA THERAPEUTICS INC | Healthcare | 3.9% | $47.5m | 1,275,000 | 332% | added |
| 8 | PLRX PLIANT THERAPEUTICS INC | Healthcare | 3.7% | $44.6m | 1,675,000 | 0% | held |
| 9 | RVMD REVOLUTION MEDICINES INC | Healthcare | 3.2% | $39.2m | 1,810,000 | -28% | reduced |
| 10 | EXK EXACT SCIENCES CORP | Basic Materials | 3.2% | $38.3m | 565,000 | 0% | held |
| 11 | WGS GENEDX HOLDINGS CORP | 3.1% | $37.3m | 102,151,785 | 521% | added | |
| 12 | SOMALOGIC INC | 2.7% | $32.1m | 12,604,275 | 0% | held | |
| 13 | VERVE THERAPEUTICS INC | 2.5% | $30.6m | 2,120,571 | -7% | reduced | |
| 14 | 2655787D BLUEPRINT MEDICINES CORP | 2.5% | $30.1m | 670,000 | -55% | reduced | |
| 15 | DNLI DENALI THERAPEUTICS INC | Healthcare | 2.5% | $30.0m | 1,300,000 | 0% | held |
| 16 | MXCT MAXCYTE INC | 2.0% | $24.4m | 4,925,000 | -48% | reduced | |
| 17 | 2SEVENTY BIO INC | 1.7% | $20.6m | 2,023,913 | 9% | added | |
| 18 | ABCL ABCELLERA BIOLOGICS INC | Healthcare | 1.6% | $19.0m | 2,520,000 | 11% | added |
| 19 | MIRATI THERAPEUTICS INC | 1.6% | $19.0m | 510,000 | 7% | added | |
| 20 | 4D MOLECULAR THERAPEUTICS IN | 1.5% | $18.4m | 1,070,000 | 70% | added | |
| 21 | BEAM BEAM THERAPEUTICS INC | Healthcare | 1.4% | $17.5m | 570,000 | 54% | added |
| 22 | TNYA TENAYA THERAPEUTICS INC | 1.4% | $17.3m | 6,078,860 | 0% | held | |
| 23 | GPCR STRUCTURE THERAPEUTICS INC | Healthcare | 1.3% | $16.1m | 677,017 | – | new |
| 24 | PROMETHEUS BIOSCIENCES INC | 1.3% | $16.1m | 150,000 | 0% | held | |
| 25 | AVIDITY BIOSCIENCES INC | 1.1% | $13.0m | 850,000 | 0% | held | |
| 26 | FATE FATE THERAPEUTICS INC | Healthcare | 1.0% | $11.7m | 2,050,000 | 0% | held |
| 27 | IPSC CENTURY THERAPEUTICS INC | Healthcare | 0.9% | $11.1m | 3,206,380 | 0% | held |
| 28 | TWST TWIST BIOSCIENCE CORP | Healthcare | 0.9% | $10.6m | 700,000 | -26% | reduced |
| 29 | ABSI ABSCI CORPORATION | 0.8% | $9.4m | 5,393,260 | -27% | reduced | |
| 30 | PRME PRIME MEDICINE INC | 0.7% | $9.0m | 734,350 | 0% | held | |
| 31 | DICE THERAPEUTICS INC | 0.7% | $8.9m | 310,000 | 88% | added | |
| 32 | OPRX OPTIMIZERX CORP | Healthcare | 0.6% | $7.3m | 500,000 | 92% | added |
| 33 | INCY INCYTE CORP | Healthcare | 0.5% | $5.6m | 77,500 | 0% | held |
| 34 | GLUE MONTE ROSA THERAPEUTICS INC | 0.3% | $4.0m | 510,882 | 0% | held | |
| 35 | TNGX TANGO THERAPEUTICS INC | Healthcare | 0.3% | $4.0m | 1,000,000 | – | new |
| 36 | SINGULAR GENOMICS SYSTEMS IN | 0.1% | $1.6m | 1,345,722 | 0% | held | |
| 37 | INVITAE CORP | 0.1% | $1.4m | 1,038,388 | -89% | reduced | |
| 38 | EXSCIENTIA PLC | 0.1% | $1.1m | 213,900 | 0% | held | |
| 39 | LIANY LIANBIO | 0.0% | $402.5k | 206,415 | 0% | held | |
| 40 | KRONOS BIO INC | 0.0% | $180.8k | 123,839 | 0% | held |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.